Forma

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

Retrieved on: 
Wednesday, March 8, 2023
Novo Nordisk, Education, Sanofi, University of Massachusetts Amherst, Acquisition, Office management, Therapy, Forma, Culture, Human resources, Swedish Orphan Biovitrum, Linea, University, Patient, Industrial Affairs Committee (Iceland), Management, Editas Medicine, Genzyme

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer.

Key Points: 
  • CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer.
  • Ms. Aspesi will lead Editas’ human resources department and the Company’s people strategy in support of its mission and goals.
  • I look forward to working with Linea and the Leadership Team to help drive our talented team towards our goal of becoming a commercial-stage organization and transforming the lives of people living with serious diseases,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.
  • I am excited to partner with our Leadership Team and our employees to make an impact in the lives of patients around the world,” said Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine.

Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Computational chemistry, JAK2, DMPK, Chemistry, BET, IND, Novartis Institute for Tropical Diseases, Novartis, Nimbus, University, Pancreatic serous cystadenoma, Biocon, IDH1, Forma, Therapy, Biomedical Research, Patient, JAK, Disease, Drug development, Preclinical development, Ajax, Doctor of Philosophy, TYK2, Sanofi, MPN, Senior, Pharmaceutical industry, Safety

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.
  • Dr. Collis brings over 25 years of drug development experience to Ajax with previous preclinical development roles at Novartis, Forma Therapeutics and Nimbus Therapeutics.
  • “We are excited to have Alan join Ajax as we transition our lead Type II JAK2 inhibitor program into IND enabling studies,” said Martin Vogelbaum, CEO of Ajax Therapeutics.
  • Prior to Syngene, he served as Senior Vice President of Preclinical Development at Nimbus Therapeutics where led the preclinical and IND activities for the company’s TYK2 and HPK-1 inhibitor programs.

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Retrieved on: 
Monday, February 27, 2023
Alcon, Therapy, University, Tufts University, Bachelor of Science, MBA, Chemical Corps, Chemistry, University of California, Berkeley, Sinusitis, LYRA, Patient, Doctor of Philosophy, Laboratory, CMC, Employment, CRS, Novo Nordisk, United States Department of the Army, Takeda Oncology, Pharmaceutical industry, Northeastern University, Takeda, Forma, Science, Lyra

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023.

Key Points: 
  • WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023.
  • “We are pleased to welcome Dr. Bishop to Lyra as we advance our in-house manufacturing systems for our proprietary drug-eluting matrix from clinical to commercial stage,” said Maria Palasis, Ph.D., Chief Executive Officer of Lyra.
  • “The manufacturing capabilities of Lyra, which uniquely combine drug quality systems with device manufacturing operations, are impressive.
  • He joins Lyra from Forma Therapeutics (acquired by Novo Nordisk), where he was Chief Technology Officer.

Configit's Ace Becomes a Unity Verified Solution, Delivering an Immersive 3D Product Configuration Experience for Customers

Retrieved on: 
Wednesday, February 8, 2023
API, CLM, Configuration lifecycle management, 3D, Video game, Bridge, 3D printing, Forma

COPENHAGEN, Denmark, Feb. 8, 2023 /PRNewswire/ -- Configit, the global leader in Configuration Lifecycle Management (CLM), today announced that its Configit Ace® is now a Unity Verified Solution. Additionally, the two companies have co-developed a connector between the Configit Ace and Unity Forma, providing manufacturers with best-in-class configuration and 3D visualization technology. This enables manufacturers to provide self-service to their end-customers of highly complex products using a 3D product configurator.

Key Points: 
  • Additionally, the two companies have co-developed a connector between the Configit Ace and Unity Forma, providing manufacturers with best-in-class configuration and 3D visualization technology.
  • This enables manufacturers to provide self-service to their end-customers of highly complex products using a 3D product configurator.
  • Johan Salenstedt, CEO of Configit, said: "Becoming part of Unity's Verified Solution ecosystem will enable us to help more customers with enhanced product configuration functionality.
  • Our Configit Ace® API will provide an immersive 3D experience of the product for customers.

Configit's Ace Becomes a Unity Verified Solution, Delivering an Immersive 3D Product Configuration Experience for Customers

Retrieved on: 
Wednesday, February 8, 2023
API, CLM, Configuration lifecycle management, 3D, Video game, Bridge, 3D printing, Forma

COPENHAGEN, Denmark, Feb. 8, 2023 /PRNewswire/ -- Configit, the global leader in Configuration Lifecycle Management (CLM), today announced that its Configit Ace® is now a Unity Verified Solution. Additionally, the two companies have co-developed a connector between the Configit Ace and Unity Forma, providing manufacturers with best-in-class configuration and 3D visualization technology. This enables manufacturers to provide self-service to their end-customers of highly complex products using a 3D product configurator.

Key Points: 
  • Additionally, the two companies have co-developed a connector between the Configit Ace and Unity Forma, providing manufacturers with best-in-class configuration and 3D visualization technology.
  • This enables manufacturers to provide self-service to their end-customers of highly complex products using a 3D product configurator.
  • Johan Salenstedt, CEO of Configit, said: "Becoming part of Unity's Verified Solution ecosystem will enable us to help more customers with enhanced product configuration functionality.
  • Our Configit Ace® API will provide an immersive 3D experience of the product for customers.

LAVA Therapeutics Announces Appointment of New Directors to the Board

Retrieved on: 
Friday, January 6, 2023
Cancer, Takeda Pharmaceutical Company, MedImmune, LAVA, Biotechnology, Drug discovery, Therapy, Drug development, Research, Knowledge, Immunotherapy, Mallinckrodt, University of Oxford, AstraZeneca, Bachelor of Science in Human Biology, Control, Louis Charles Kiener, University, Lancaster University, Sucampo Pharmaceuticals, Takeda Oncology, Sir William Dunn School of Pathology, Doctor of Philosophy, Fine chemical, Forma, Science, Pathology, Takeda

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of two new directors to its Board of Directors.

Key Points: 
  • UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of two new directors to its Board of Directors.
  • Additionally, Guido Magni, M.D., Ph.D. will step down from his role on the LAVA Board.
  • Kiener and Ms. Wadlinger bring a wealth of knowledge in their respective fields along with deep expertise in biotechnology.
  • “Since joining our board in 2018, Dr. Magni has made invaluable contributions to LAVA, including lead program selection, launching our first clinical trials and seeing LAVA through a successful initial public offering.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FMTX, ECOM, SMBC, COWN

Retrieved on: 
Tuesday, October 4, 2022
NASDAQ, Fraud, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., ChannelAdvisor, Novo Nordisk, Cowen Inc., TD, Therapy, NYSE, Toronto-Dominion Bank, Sale, CommerceHub, Advertising, GLOBE, Forma, Security (finance), Citizenship

If you are a Forma shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Forma shareholder, click here to learn more about your rights and options .
  • If you are a ChannelAdvisor shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, AERI, FMTX, CSVI

Retrieved on: 
Monday, October 3, 2022
OTCQX, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Centerbridge Partners, Novo Nordisk, NASDAQ, Fraud, Therapy, Advertising, Outsourcing, Forma, Security (finance)

If you are a Computer Services shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Computer Services shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

PENELOPE and the Beauty Bar's MEDISPA Division Celebrates First Anniversary, Introduces New MediSpa Treatments

Retrieved on: 
Monday, October 3, 2022
Smart contract, Muscle, MBR, Incontinence, FDA, EMS, Fairmont Olympic Hotel, Abdomen, Robert-Bourassa Boulevard — University Street, Beauty, Hair removal, Time-invariant system, PRP, IPL, Electrical muscle stimulation, Recherche, Forma, Beauty salon

Seattle's PENELOPE and the Beauty Bar Celebrates First Anniversary of MediSpa Division, Introduces New MediSpa Treatments

Key Points: 
  • Seattle's PENELOPE and the Beauty Bar Celebrates First Anniversary of MediSpa Division, Introduces New MediSpa Treatments
    Three new MediSpa treatments are being added to the current menu this fall.
  • RF toning, which utilizes Electrical Muscle Stimulation (EMS) which helps refine, restore, and improve the look and strength of muscles in the abdomen.
  • PENELOPE and the Beauty Bar is located in the historic Fairmont Olympic Hotel at 411 University Street, Seattle, WA 98101.
  • For more information on PENELOPE and the Beauty Bar and PENELOPE MEDISPA, please visit www.penelopeandthebeautybar.com .

Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

Retrieved on: 
Friday, September 30, 2022
Content Marketing, Other Communications, Genetics, Public Relations, Investor Relations, Communications, Media, Other Health, Managed Care, General Health, Health, Therapy, Health, PSA, Sickle cell disease, Center, Oxygen, National Heart, Lung, and Blood Institute, Forma, Blood, RBC, Association, Hemolytic anemia, Organization, LinkedIn, Senior, Life, United, Partnership, Stroke, MDS, Thalassemia, Patient, Lung, CEO, SCD, Pain, PKR, Degenerative disease, Quality of life, Public service announcement, Radio, Sickle Cell Disease Association of America, Nasdaq, Centers for Disease Control and Prevention, United States $1 Coin Act of 1997, Life expectancy, Tissue, Korea Disease Control and Prevention Agency, European Medicines Agency, Human, Research, Capillary, Awareness, Multimedia, African Americans, Cancer, Disease, Fela Kuti, Pharmaceutical industry

The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (Nasdaq: FMTX) today announced that they have joined forces to create a public service announcement (PSA) to drive awareness and advance meaningful understanding of sickle cell disease (SCD).

Key Points: 
  • The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (Nasdaq: FMTX) today announced that they have joined forces to create a public service announcement (PSA) to drive awareness and advance meaningful understanding of sickle cell disease (SCD).
  • campaign urges viewers to imagine they are experiencing the agonizing but unseen pain that is faced by people who live with SCD.
  • This incredibly powerful PSA brings the experience of living with SCD to life and makes it extraordinarily real for the viewers.
  • The association and more than 50 member organizations support sickle cell research, public and professional health education and patient and community services.